<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01929083</url>
  </required_header>
  <id_info>
    <org_study_id>12GRNT12060187</org_study_id>
    <nct_id>NCT01929083</nct_id>
  </id_info>
  <brief_title>Influence of Progesterone Administration on Drug-Induced QT Interval Lengthening</brief_title>
  <official_title>Influence of Progesterone Administration on Drug-Induced QT Interval Prolongation and Torsades de Pointes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Indiana University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>American Heart Association</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Indiana University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Female sex is an independent risk factor for the potentially fatal drug-induced arrhythmia
      (irregular heartbeat) known as torsades de pointes (TdP), which is associated with
      prolongation of the corrected QT (QTc) interval on the electrocardiogram (ECG). Mechanisms
      for this increased risk in women are not well-understood. QTc interval duration has been
      shown to fluctuate throughout the phases of the menstrual cycle. Evidence indicates that the
      QTc interval response to drugs that may cause TdP is greater during the menses and ovulation
      phases of the menstrual cycle, during which serum progesterone concentrations are lowest, and
      lesser during the luteal phase, during which serum progesterone concentrations are highest.
      Additional evidence from our laboratory suggests that progesterone may be protective against
      TdP. Specific Aim 1: Establish the influence of oral progesterone administration as a
      preventive method by which to diminish the degree of drug-induced QT interval prolongation in
      women. Working hypothesis: Oral progesterone administration effectively attenuates enhanced
      drug-induced QT interval response in women. To test this hypothesis, progesterone or placebo
      will be administered in a crossover fashion to women during the menses phase of the menstrual
      cycle. QTc interval response to low-dose ibutilide, a drug known to lengthen the QT interval,
      will be assessed. The primary endpoint will be individually-corrected QT interval (QTcI)
      response to ibutilide, in the presence and absence of progesterone, which will be assessed
      by: 1) Effect on maximum change in QTcI, and 2) Area under the QTcI interval-time curves
      (AUEC). At the conclusion of this study, we will have established that oral progesterone
      administration is a safe and effective method of attenuating drug-induced QT interval
      prolongation.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2013</start_date>
  <completion_date type="Actual">June 2014</completion_date>
  <primary_completion_date type="Actual">June 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Baseline (Pre-Ibutilide) QTcI Intervals</measure>
    <time_frame>After 7 days of progesterone or placebo, prior to receiving IV ibutilide</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Individual-corrected QT Interval (QTcI)</measure>
    <time_frame>0, 15 &amp; 30 minutes, and 1, 2, 4, 6, 8, and 12 hours post-ibutilide administration</time_frame>
    <description>QT intervals will be corrected as follows: Prior to randomization, subjects will come to the Indiana Clinical Research Center for a 12-hour stay, during which three ECGs, one minute apart, will be obtained at the following times: 0, 15 &amp; 30 minutes, and 1, 2, 4, 6, 8, and 12 hours. Subjects will be discharged, and then return then next morning for the 24 hour ECG. QT and RR intervals will be used to determine each subject's individual rate-corrected QT interval (QTcI) using the parabolic model QT = β•RRα, where RR is the interval between adjacent QRS complexes, and α and β are subject-specific correction factors.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum % Change From Baseline in QTcI Intervals Following Ibutilide Administration</measure>
    <time_frame>After 7 days of progesterone or placebo</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the QTcI - Time Curve (AUEC)</measure>
    <time_frame>From beginning of 10-minute ibutilide infusion to 1 hour following ibutilide infusion</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of Progesterone-associated Adverse Effects Compared to Placebo</measure>
    <time_frame>During 7 days of treatment with oral progesterone or placebo</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Adverse Effects Associated With Ibutilide in the Progesterone and Placebo Phases</measure>
    <time_frame>Within 8 hours following ibutilide administration</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Maximum (Peak) Serum Ibutilide Concentrations During Progesterone and Placebo Phases</measure>
    <time_frame>Within 1 hour following ibutilide administration (0, 15 &amp; 30 minutes and 1 hours.)</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Serum Estradiol Concentrations During the Progesterone and Placebo Phases</measure>
    <time_frame>Following 7 days of progesterone or placebo</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Serum Progesterone Concentrations During Progesterone and Placebo Phases</measure>
    <time_frame>After 7 days of progesterone or placebo</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Ratio of Serum Progesterone:Estradiol Concentrations During the Progesterone and Placebo Phases</measure>
    <time_frame>After 7 days of progesterone or placebo</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">19</enrollment>
  <condition>Prolonged QT Interval in EKG and Sudden Death</condition>
  <arm_group>
    <arm_group_label>Progesterone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive treatment with oral progesterone 400 mg once daily (two x 200 mg capsules) every evening for 7 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects will receive oral placebo, two capsules once daily every evening for 7 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Progesterone</intervention_name>
    <description>Subjects will receive oral progesterone 400 mg (two x 200 mg capsules) once daily every evening for 7 days</description>
    <arm_group_label>Progesterone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Subjects will receive oral placebo two capsules once daily every evening for 7 days</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ibutilide</intervention_name>
    <description>Ibutilide 0.003 mg/kg administered to all subjects to moderately lengthen the QT interval</description>
    <arm_group_label>Progesterone</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female

          -  Age 21-40 years

          -  Premenopausal

        Exclusion Criteria:

        Serum potassium ,&lt; 3.6 meq/l

          -  Serum magnesium &lt; 1.8 mg/dl

          -  Serum hemoglobin &lt; 9.0 mg/dl

          -  Serum hematocrit &lt; 26%

          -  Hypertension

          -  Coronary artery disease

          -  Heart failure

          -  Liver disease

          -  Kidney disease

          -  Serum creatinine &gt; 1.5 mg/dl

          -  Taking hormone contraceptives

          -  Baseline Bazett's correct QTc interval &gt; 450 ms

          -  Family history of long-QT syndrome, arrhythmias, sudden cardiac death

          -  Concomitant use of any QT prolonging drug

          -  Pregnancy

          -  weight &lt; 45 kg

          -  Unwillingness to use non-hormonal forms of birth control during the study period
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James E Tisdale, BSc, PharmD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Purdue University &amp; Indiana University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Indiana Clinical Research Center</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Purdue University</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 22, 2013</study_first_submitted>
  <study_first_submitted_qc>August 26, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 27, 2013</study_first_posted>
  <results_first_submitted>August 27, 2015</results_first_submitted>
  <results_first_submitted_qc>August 27, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 28, 2015</results_first_posted>
  <last_update_submitted>October 29, 2015</last_update_submitted>
  <last_update_submitted_qc>October 29, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 30, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Purdue University</investigator_affiliation>
    <investigator_full_name>James E. Tisdale</investigator_full_name>
    <investigator_title>Professor of Pharmacy Practice</investigator_title>
  </responsible_party>
  <keyword>Torsades de pointes</keyword>
  <keyword>Progesterone</keyword>
  <keyword>Clinical trial</keyword>
  <keyword>Risk reduction</keyword>
  <keyword>Electrocardiography</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Death, Sudden</mesh_term>
    <mesh_term>Torsades de Pointes</mesh_term>
    <mesh_term>Long QT Syndrome</mesh_term>
    <mesh_term>Jervell-Lange Nielsen Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Progesterone</mesh_term>
    <mesh_term>Ibutilide</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects recruited from a) INResearch database, maintained by Indiana Clinical Translational Research Institute (CTSI), and b) Hard copy and electronic advertisements on the IUPUI and Purdue University campuses Participants were recruited between October 2012 and February 2014</recruitment_details>
      <pre_assignment_details>n=333 subjects assessed for eligibility; n=27 consented, n=306 excluded (n=108 did not meet inclusion criteria, n=198 declined to participate); of n=27 consented, n=19 enrolled, n=8 excluded because they met one or more exclusion criteria</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Progesterone First, Then Placebo</title>
          <description>Subjects will receive treatment with oral progesterone 400 mg once daily (two x 200 mg capsules) every evening for 7 days
Progesterone: Subjects will receive oral progesterone 400 mg (two x 200 mg capsules) once daily every evening for 7 days</description>
        </group>
        <group group_id="P2">
          <title>Placebo First, Then Progesterone</title>
          <description>Subjects will receive oral placebo, two capsules once daily every evening for 7 days
Placebo: Subjects will receive oral placebo two capsules once daily every evening for 7 days</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Intervention 1</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10">Number of patients randomized to receive progesterone first</participants>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Returned for 1st Ibutilide Administratio</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Nonadherent to study medications</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Intervention 2</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Returned for 2nd Ibutilide Administratio</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Includes n=15 subjects included in the final analysis. Includes subjects randomized to receive progesterone first and patients randomized to receive placebo first</population>
      <group_list>
        <group group_id="B1">
          <title>Entire Study Population</title>
          <description>n=15 subjects who completed the study</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="15"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29" spread="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Baseline (Pre-Ibutilide) QTcI Intervals</title>
        <time_frame>After 7 days of progesterone or placebo, prior to receiving IV ibutilide</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Progesterone</title>
            <description>Subjects will receive treatment with oral progesterone 400 mg once daily (two x 200 mg capsules) every evening for 7 days
Progesterone: Subjects will receive oral progesterone 400 mg (two x 200 mg capsules) once daily every evening for 7 days</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Subjects will receive oral placebo, two capsules once daily every evening for 7 days
Placebo: Subjects will receive oral placebo two capsules once daily every evening for 7 days</description>
          </group>
        </group_list>
        <measure>
          <title>Baseline (Pre-Ibutilide) QTcI Intervals</title>
          <units>ms</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="412" spread="15"/>
                    <measurement group_id="O2" value="419" spread="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.04</p_value>
            <method>t-test, 2 sided</method>
            <method_desc>Paired t-test</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Maximum Individual-corrected QT Interval (QTcI)</title>
        <description>QT intervals will be corrected as follows: Prior to randomization, subjects will come to the Indiana Clinical Research Center for a 12-hour stay, during which three ECGs, one minute apart, will be obtained at the following times: 0, 15 &amp; 30 minutes, and 1, 2, 4, 6, 8, and 12 hours. Subjects will be discharged, and then return then next morning for the 24 hour ECG. QT and RR intervals will be used to determine each subject’s individual rate-corrected QT interval (QTcI) using the parabolic model QT = β•RRα, where RR is the interval between adjacent QRS complexes, and α and β are subject-specific correction factors.</description>
        <time_frame>0, 15 &amp; 30 minutes, and 1, 2, 4, 6, 8, and 12 hours post-ibutilide administration</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Progesterone</title>
            <description>Subjects will receive treatment with oral progesterone 400 mg once daily (two x 200 mg capsules) every evening for 7 days
Progesterone: Subjects will receive oral progesterone 400 mg (two x 200 mg capsules) once daily every evening for 7 days</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Subjects will receive oral placebo, two capsules once daily every evening for 7 days
Placebo: Subjects will receive oral placebo two capsules once daily every evening for 7 days</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Individual-corrected QT Interval (QTcI)</title>
          <description>QT intervals will be corrected as follows: Prior to randomization, subjects will come to the Indiana Clinical Research Center for a 12-hour stay, during which three ECGs, one minute apart, will be obtained at the following times: 0, 15 &amp; 30 minutes, and 1, 2, 4, 6, 8, and 12 hours. Subjects will be discharged, and then return then next morning for the 24 hour ECG. QT and RR intervals will be used to determine each subject’s individual rate-corrected QT interval (QTcI) using the parabolic model QT = β•RRα, where RR is the interval between adjacent QRS complexes, and α and β are subject-specific correction factors.</description>
          <units>ms</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="443" spread="17"/>
                    <measurement group_id="O2" value="458" spread="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.003</p_value>
            <method>t-test, 2 sided</method>
            <method_desc>Paired t-test</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Progesterone-associated Adverse Effects Compared to Placebo</title>
        <time_frame>During 7 days of treatment with oral progesterone or placebo</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Progesterone</title>
            <description>Subjects will receive treatment with oral progesterone 400 mg once daily (two x 200 mg capsules) every evening for 7 days
Progesterone: Subjects will receive oral progesterone 400 mg (two x 200 mg capsules) once daily every evening for 7 days</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Subjects will receive oral placebo, two capsules once daily every evening for 7 days
Placebo: Subjects will receive oral placebo two capsules once daily every evening for 7 days</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Progesterone-associated Adverse Effects Compared to Placebo</title>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Fatigue/general malaise</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mood changes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Breast tenderness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hypotension</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vertigo requiring discontinuation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.04</p_value>
            <p_value_desc>P value for incidence of fatigue/malaise</p_value_desc>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.60</p_value>
            <p_value_desc>p values for incidence of headache</p_value_desc>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.23</p_value>
            <p_value_desc>p value for incidence of mood changes</p_value_desc>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.23</p_value>
            <p_value_desc>p value for incidence of breast tenderness</p_value_desc>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.48</p_value>
            <p_value_desc>p value for incidence of hypotension</p_value_desc>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.48</p_value>
            <p_value_desc>p value for incidence of vertigo requiring discontinuation of therapy</p_value_desc>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Maximum % Change From Baseline in QTcI Intervals Following Ibutilide Administration</title>
        <time_frame>After 7 days of progesterone or placebo</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Progesterone</title>
            <description>Subjects will receive treatment with oral progesterone 400 mg once daily (two x 200 mg capsules) every evening for 7 days
Progesterone: Subjects will receive oral progesterone 400 mg (two x 200 mg capsules) once daily every evening for 7 days</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Subjects will receive oral placebo, two capsules once daily every evening for 7 days
Placebo: Subjects will receive oral placebo two capsules once daily every evening for 7 days</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum % Change From Baseline in QTcI Intervals Following Ibutilide Administration</title>
          <units>percentage change from baseline value</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.5" spread="2.4"/>
                    <measurement group_id="O2" value="9.3" spread="3.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.02</p_value>
            <method>t-test, 2 sided</method>
            <method_desc>Paired t-test</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Area Under the QTcI - Time Curve (AUEC)</title>
        <time_frame>From beginning of 10-minute ibutilide infusion to 1 hour following ibutilide infusion</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Progesterone</title>
            <description>Subjects will receive treatment with oral progesterone 400 mg once daily (two x 200 mg capsules) every evening for 7 days
Progesterone: Subjects will receive oral progesterone 400 mg (two x 200 mg capsules) once daily every evening for 7 days</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Subjects will receive oral placebo, two capsules once daily every evening for 7 days
Placebo: Subjects will receive oral placebo two capsules once daily every evening for 7 days</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the QTcI - Time Curve (AUEC)</title>
          <units>ms*hr</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="497" spread="13"/>
                    <measurement group_id="O2" value="510" spread="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.002</p_value>
            <method>t-test, 2 sided</method>
            <method_desc>Paired t-test</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Adverse Effects Associated With Ibutilide in the Progesterone and Placebo Phases</title>
        <time_frame>Within 8 hours following ibutilide administration</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Progesterone</title>
            <description>Subjects will receive treatment with oral progesterone 400 mg once daily (two x 200 mg capsules) every evening for 7 days
Progesterone: Subjects will receive oral progesterone 400 mg (two x 200 mg capsules) once daily every evening for 7 days</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Subjects will receive oral placebo, two capsules once daily every evening for 7 days
Placebo: Subjects will receive oral placebo two capsules once daily every evening for 7 days</description>
          </group>
        </group_list>
        <measure>
          <title>Adverse Effects Associated With Ibutilide in the Progesterone and Placebo Phases</title>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Bradycardia (HR &lt; 60 bpm)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Burning at infusion site</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Transient QTc interval &gt; 500 ms</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.65</p_value>
            <p_value_desc>p value for bradycardia</p_value_desc>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&gt;0.99</p_value>
            <p_value_desc>p value for burning at infusion site</p_value_desc>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&gt; 0.99</p_value>
            <p_value_desc>p value for transient QTc interval &gt; 500 ms</p_value_desc>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Maximum (Peak) Serum Ibutilide Concentrations During Progesterone and Placebo Phases</title>
        <time_frame>Within 1 hour following ibutilide administration (0, 15 &amp; 30 minutes and 1 hours.)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Progesterone</title>
            <description>Subjects will receive treatment with oral progesterone 400 mg once daily (two x 200 mg capsules) every evening for 7 days
Progesterone: Subjects will receive oral progesterone 400 mg (two x 200 mg capsules) once daily every evening for 7 days</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Subjects will receive oral placebo, two capsules once daily every evening for 7 days
Placebo: Subjects will receive oral placebo two capsules once daily every evening for 7 days</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum (Peak) Serum Ibutilide Concentrations During Progesterone and Placebo Phases</title>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1247" spread="770"/>
                    <measurement group_id="O2" value="1172" spread="709"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.43</p_value>
            <method>t-test, 2 sided</method>
            <method_desc>Paired t-test</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Serum Estradiol Concentrations During the Progesterone and Placebo Phases</title>
        <time_frame>Following 7 days of progesterone or placebo</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Progesterone</title>
            <description>Subjects will receive treatment with oral progesterone 400 mg once daily (two x 200 mg capsules) every evening for 7 days
Progesterone: Subjects will receive oral progesterone 400 mg (two x 200 mg capsules) once daily every evening for 7 days</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Subjects will receive oral placebo, two capsules once daily every evening for 7 days
Placebo: Subjects will receive oral placebo two capsules once daily every evening for 7 days</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Estradiol Concentrations During the Progesterone and Placebo Phases</title>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89.3" spread="62.8"/>
                    <measurement group_id="O2" value="71.8" spread="31.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.36</p_value>
            <method>t-test, 2 sided</method>
            <method_desc>Paired t-test</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Serum Progesterone Concentrations During Progesterone and Placebo Phases</title>
        <time_frame>After 7 days of progesterone or placebo</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Progesterone</title>
            <description>Subjects will receive treatment with oral progesterone 400 mg once daily (two x 200 mg capsules) every evening for 7 days
Progesterone: Subjects will receive oral progesterone 400 mg (two x 200 mg capsules) once daily every evening for 7 days</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Subjects will receive oral placebo, two capsules once daily every evening for 7 days
Placebo: Subjects will receive oral placebo two capsules once daily every evening for 7 days</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Progesterone Concentrations During Progesterone and Placebo Phases</title>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.2" spread="11.0"/>
                    <measurement group_id="O2" value="1.2" spread="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>t-test, 2 sided</method>
            <method_desc>Paired t-test</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Ratio of Serum Progesterone:Estradiol Concentrations During the Progesterone and Placebo Phases</title>
        <time_frame>After 7 days of progesterone or placebo</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Progesterone</title>
            <description>Subjects will receive treatment with oral progesterone 400 mg once daily (two x 200 mg capsules) every evening for 7 days
Progesterone: Subjects will receive oral progesterone 400 mg (two x 200 mg capsules) once daily every evening for 7 days</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Subjects will receive oral placebo, two capsules once daily every evening for 7 days
Placebo: Subjects will receive oral placebo two capsules once daily every evening for 7 days</description>
          </group>
        </group_list>
        <measure>
          <title>Ratio of Serum Progesterone:Estradiol Concentrations During the Progesterone and Placebo Phases</title>
          <units>Ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="205" spread="40"/>
                    <measurement group_id="O2" value="18" spread="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0001</p_value>
            <method>t-test, 2 sided</method>
            <method_desc>Paired t-test</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>During 7 days of therapy with progesterone or placebo</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Progesterone</title>
          <description>Subjects will receive treatment with oral progesterone 400 mg once daily (two x 200 mg capsules) every evening for 7 days
Progesterone: Subjects will receive oral progesterone 400 mg (two x 200 mg capsules) once daily every evening for 7 days</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Subjects will receive oral placebo, two capsules once daily every evening for 7 days
Placebo: Subjects will receive oral placebo two capsules once daily every evening for 7 days</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo requiring discontinuation of therapy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Breast tenderness</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue/general malaise</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="16"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Mood changes</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. James E Tisdale</name_or_title>
      <organization>Indiana University</organization>
      <phone>317-880-5418</phone>
      <email>jtisdale@purdue.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

